Long QT Syndrome (LQTS) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

 

Long QT Syndrome (LQTS) could be a congenital or acquired heterogeneous syndrome that predisposes patients to arrhythmogenic syncope, seizures, and sudden cardiac death (SCD). Clinically, LQTS shows a lifelong asymptomatic state with no electrocardiographic (ECG) findings, and it is generally an asymptomatic state for life. Frequent and recurrent LQTS triggers emotional or physical stress and leads to SCD. The electrocardiographic QT interval represents the cardiac action potential's depolarization and repolarization phases. The interplay of several ion channels determines the action potential duration. Decreases in repolarizing outward K+ currents or increases in depolarizing inward sodium or calcium currents can prolong the QT interval, thus representing a pathophysiological substrate for LQTS. KCNQ1 (LQT1), KCNH2 (LQT2), and SCN5A (LQT3) are the most common LQTS genes, accounting for ≈90% of all genotype-positive cases. Heterozygous KCNQ1 mutations cause the dominant RW LQT1 syndrome and account for most disease-causing variants. Homozygous mutations in KCNQ1, or compound heterozygous mutations, cause the recessive JLN variant characterized by deafness because of the reduced IKs in the inner ear.

 

Thelansis’s “Long QT Syndrome (LQTS) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Long QT Syndrome (LQTS) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Long QT Syndrome (LQTS) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Long QT Syndrome (LQTS) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Long QT Syndrome (LQTS) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033